Bryan Johnson: I Just Took the Most Powerful Dose of DMT in the World... Here's What It Was Like

This episode brings in Bryan Johnson, and the discussion moves from psychedelics into longevity, founder identity, AI, experimentation and how quickly humans may need to adapt.

Key points

• Johnson treats longevity as an evidence-ranking problem. His team starts with interventions that have the strongest evidence and effect sizes, from exercise, sleep and nutrition down to more experimental therapies, rather than beginning with whatever sounds most novel.

• Psychedelics entered his program because the data became interesting. He says psilocybin appeared to affect inflammation, brain connectivity and metabolic markers, which led him to test whether compounds like 5-MeO-DMT might have broader rejuvenation effects.

• He separates subjective experience from measured evidence. Johnson describes 5-MeO as profoundly transformative, but when asked what the scans showed, he says they did not know yet; MRI, EEG and other measurements had been collected, but analysis was still pending.

• The conversation treats psychological flexibility as a form of adaptability. Johnson argues that people develop increasingly rigid mental patterns with age, while rapid technological change may reward the ability to reconstruct assumptions, identity and priorities much faster.

• Founder transformation can become an investor risk. The hosts describe entrepreneurs who reportedly changed their lives radically after psychedelic experiences, and Johnson recounts an investor who put restrictions into deal documents because of the fear of effectively “losing the founder.”

• Johnson’s model is high-risk experimentation with heavy instrumentation. He repeatedly emphasizes controlled settings, careful measurement and professional supervision, while acknowledging that powerful interventions can produce serious psychological or behavioral consequences.

• Organoids could make personal experimentation faster and cheaper. Johnson is creating tissue models from his own cells so compounds can eventually be tested on versions of his heart, liver and other organs before relying entirely on experiments inside his body.

• AI is becoming an execution accelerator for frontier research. When a biological project is described as a two-year build, the group notes how much AI-assisted project management has improved in only six months, potentially shrinking the time and team size required for complex programs.

The central idea

The episode is really about increasing the speed at which a person can experiment, measure and change.

Johnson’s worldview combines extreme openness to new technologies with unusually heavy measurement. The recurring tension is whether faster self-modification creates a genuine advantage — or introduces new risks faster than institutions, investors and individuals can understand them.